Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Dusseldorf - Delayed Quote EUR

Eli Lilly and Co (LLY0.DU)

Compare

20.80

+0.40

+(1.96%)

At close: February 21 at 7:30:55 PM GMT+1

Eli Lilly (NYSE:LLY) stock performs better than its underlying earnings growth over last five years

For many, the main point of investing in the stock market is to achieve spectacular returns. And we've seen some truly...

Simply Wall St. yesterday

LLY
Hims Stock Crashes After FDA Resolves Weight-Loss Drugs Shortage

HIMS stock fell after the FDA said the shortages in Novo Nordisk's weight-loss drug has been resolved.

Investor's Business Daily 2 days ago

LLY

NONOF

NVO
These stocks are now among the S&P 500's top contributors

Is the stock market beginning to be less reliant on Big Tech gains, leaning more to the tune of other key sectors and mega-cap names? Yahoo Finance host Seana Smith explains the S&P 500's (^GSPC) top drivers in 2025 so far, as JPMorgan Chase & Co. (JPM), Visa (V), Walmart (WMT), and Eli Lilly (LLY) are among the market average's biggest contributors behind Magnificent Seven member stocks Meta Platforms (META) and Nvidia (NVDA). Roundhill Investments CEO David Mazza spoke with Yahoo Finance earlier today, characterizing the market as climbing "another classic wall of worry." To watch more expert insights and analysis on the latest market action, check out more Asking for a Trend here. This post was written by Luke Carberry Mogan.

Yahoo Finance Video 3 days ago

LLY

META

V
'Health insurance companies are always going to need a PBM': CVS president Prem Shah

CVS is fighting to protect its PBM business as Trump and Congress look for ways to take out the pharmacy "middlemen."

Yahoo Finance 4 days ago

CVS

PFE

GDRX
Lilly to participate in TD Cowen's 45th Annual Health Care Conference

Eli Lilly and Company (NYSE: LLY) will participate in TD Cowen's 45th Annual Health Care Conference on March 4, 2025. Jake Van Naarden, executive vice president and president, Lilly Oncology, will take part in a fireside chat at 1:50 p.m., Eastern time.

PR Newswire 5 days ago

LLY
Can Eli Lilly and Company (NYSE:LLY) Maintain Its Strong Returns?

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

Simply Wall St. 5 days ago

LLY
Moderna's Q4 loss: Can the pharma giant get to profitability?

Pharmaceutical giant Moderna (MRNA) released mixed fourth quarter results on Friday, posting revenue of $966 million (higher than the consensus estimate of $954 million) alongside a wider-than-expected loss per share of $2.91. Jefferies Biotech Analyst Michael Yee speaks with Brad Smith and Madison Mills on the Morning Brief on Moderna's release, commenting that the drugmaker continues to "[remain] in a very challenging position" as the path to profitability falls out of sight. Spikevax, the company's COVID-19 vaccine, managed to bring in $3.1 billion across 2024. "While there is the Merck (MRK) cancer vaccine, the Phase 3 CMV vaccine, and the norovirus vaccine, the CMV vaccine has been delayed. The data has not hit, and they sound like they're pushing it out to later this year," Yee says on the other vaccine projects Jefferies is "cautiously optimistic" on. Yee also comments on the tightening GLP-1 weight-loss drug race between Eli Lilly (LLY), Novo Nordisk (NVO), and Amgen (AMGN). To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. This post was written by Luke Carberry Mogan.

Yahoo Finance Video 9 days ago

MRNA

AMGN

LLY
Hims & Hers stock sees another spike in trading days after Super Bowl ad

Retail investors are boosting Hims & Hers after the success of its Super Bowl ad Sunday.

Yahoo Finance 10 days ago

LLY

HIMS

NONOF
Eli Lilly and Company's (NYSE:LLY) large institutional owners must be happy as stock continues to impress, up 4.7% over the past week

Key Insights Significantly high institutional ownership implies Eli Lilly's stock price is sensitive to their trading...

Simply Wall St. 11 days ago

LLY
Why the 'best hedge' against the AI rally losing steam in 2025 is healthcare: Morning Brief

Investors have largely abandoned much of the healthcare space in favor of tech. But as tech falters, some strategists see the underrated sector as being the perfect tech hedge.

Yahoo Finance 11 days ago

IBB

NONOF

NVO
Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business

Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.

The Wall Street Journal 13 days ago

LLY

HIMS
IBD 50 Stock Hims & Hers Faces Backlash Over Provocative Super Bowl Ad

Hims stock surged into a profit-taking zone Friday after facing backlash over its provocative Super Bowl ad that criticized the makers of approved weight-loss drugs. On Friday, Sen. Richard Durbin (D-Ill.) and Sen. Roger Marshall (R-Kan.) sent a letter to acting Food and Drug Administration Commissioner Sarah Brenner asking the agency to investigate Hims for "misleading patients."

Investor's Business Daily 16 days ago

NONOF

NVO

HIMS
Eli Lilly Full Year 2024 Earnings: EPS Misses Expectations

Eli Lilly ( NYSE:LLY ) Full Year 2024 Results Key Financial Results Revenue: US$45.0b (up 32% from FY 2023). Net...

Simply Wall St. 16 days ago

LLY
Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years

Eli Lilly and Company (NYSE: LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to severely active Crohn's disease receiving two years of continuous treatment with Omvoh® (mirikizumab-mrkz) achieved long-term clinical and endoscopic outcomes, including those (43.8%) with previous biologic failure. Data from this study will be presented at the Crohn's and Colitis Congress (CCC), being held from February 6-8, 2025 in San Franci

PR Newswire 16 days ago

LLY
The Drug Industry Is Having Its Own DeepSeek Moment

It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their U.S. counterparts.

The Wall Street Journal 16 days ago

VKTX

SMMT

XBI
Stock Market Today: Dow Jones Dives As Nvidia Rises On DeepSeek Ban Report; Cathie Wood Stock Crashes On Earnings (Live Coverage)

The Dow Jones rose on Thursday while the S&P 500 and Nasdaq built more support at the 50-day moving average in the stock market today.

Investor's Business Daily 17 days ago

RBLX

AMZN

MSTEP
Eli Lilly Jumps, Reversing Its Weight-Loss Setback, On A Strong 2025 Outlook

Eli Lilly stock rose Thursday despite lighter-than-expected sales of its weight-loss and diabetes drugs Zepbound and Mounjaro.

Investor's Business Daily 17 days ago

LLY
Viking Therapeutics Plunged 6% On Its Earnings Report. Here's Why.

Viking Therapeutics stock plunged early Thursday on an earnings report that included mostly incremental updates for its weight-loss drugs.

Investor's Business Daily 17 days ago

VKTX

NONOF

NVO
Eli Lilly, Bristol Myers Squibb, Peloton: Market Minute

Yahoo Finance Anchor Josh Lipton recaps the top stories on Wall Street as part of today's Market Minute. US stocks (^DJI, ^GSPC, ^IXIC) are mixed ahead of Amazon's (AMZN) earnings print. Eli Lilly (LLY) stock is in focus after the company reported better-than-expected results and issued a strong outlook. Bristol-Myers Squibb (BMY) shares are under pressure after the company provided soft guidance due to competition among generic drugmakers. Peloton (PTON) stock jumps after beating on earnings and announcing upbeat guidance. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute. This post was written by Naomi Buchanan.

Yahoo Finance Video 17 days ago

BMY

CELG-RT

PTON
The Obesity Market Is Growing Just Fine. But Investors Want to Know What’s Next

Eli Lilly and Novo Nordisk have both assuaged investor concerns over near-term growth. Now the focus shifts back to their pipelines.

The Wall Street Journal 17 days ago

LLY

Performance Overview

Return	LLY0.DU	S&P 500
YTD	+16.52%	+2.24%
1-Year	+10.05%	+20.70%
3-Year	+10.05%	+38.27%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Eli Lilly and Co (LLY0.DU)

Eli Lilly (NYSE:LLY) stock performs better than its underlying earnings growth over last five years

Hims Stock Crashes After FDA Resolves Weight-Loss Drugs Shortage

These stocks are now among the S&P 500's top contributors

'Health insurance companies are always going to need a PBM': CVS president Prem Shah

Lilly to participate in TD Cowen's 45th Annual Health Care Conference

Can Eli Lilly and Company (NYSE:LLY) Maintain Its Strong Returns?

Moderna's Q4 loss: Can the pharma giant get to profitability?

Hims & Hers stock sees another spike in trading days after Super Bowl ad

Eli Lilly and Company's (NYSE:LLY) large institutional owners must be happy as stock continues to impress, up 4.7% over the past week

Why the 'best hedge' against the AI rally losing steam in 2025 is healthcare: Morning Brief

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business

IBD 50 Stock Hims & Hers Faces Backlash Over Provocative Super Bowl Ad

Eli Lilly Full Year 2024 Earnings: EPS Misses Expectations

Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years

The Drug Industry Is Having Its Own DeepSeek Moment

Stock Market Today: Dow Jones Dives As Nvidia Rises On DeepSeek Ban Report; Cathie Wood Stock Crashes On Earnings (Live Coverage)

Eli Lilly Jumps, Reversing Its Weight-Loss Setback, On A Strong 2025 Outlook

Viking Therapeutics Plunged 6% On Its Earnings Report. Here's Why.

Eli Lilly, Bristol Myers Squibb, Peloton: Market Minute

The Obesity Market Is Growing Just Fine. But Investors Want to Know What’s Next

Performance Overview